News
Glaucoma is one of the world’s leading causes of irreversible blindness, and currently, no therapies exist to directly protect retinal ganglion cells (RGC) from degradation and loss. NIH inventors have developed a method to treat glaucoma using exosomes derived from bone marrow-derived mesenchymal
World Intellectual Property (IP) Day is April 25th. This is a global event dedicated to industry inventors, creators, and entrepreneurs and how they achieve their goals through the use of IP. To celebrate, the Licensing Executives Society (LES) is hosting a free webinar to bring people together
In just eight years, the NIH National Institute of Allergy and Infectious Diseases moved from identifying an ultra-rare genetic disorder, CD55 deficiency, hyperactivation of the complement, angiopathic thrombosis, and protein-losing enteropathy (CHAPLE) to FDA approval of its first treatment option
Learn from NIH’s Steve Ferguson during the Licensing Executives Society (LES) Industry, Universities and Government virtual course. Ferguson is a Special Advisor at OTT and brings 30+ years of experience on how to set up successful partnerships with NIH and utilize a variety of available